Partisan perspectives in the medical literature: A study of high frequency editorialists favoring hormone replacement therapy

Journal of General Internal Medicine

Volumn 25, Issue 9, 2010, Pages 914-919

  Tatsioni, Athina ^a,c   Siontis, George C M ^a   Ioannidis, John P A ^a,b,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b INSTITUTE OF COMPUTER SCIENCE   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hormone replacement therapy; menopause; postmenopausal women

Indexed keywords

ESTROGEN; GESTAGEN; HORMONE;

ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; DEMENTIA; FRACTURE; HORMONE SUBSTITUTION; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; MENOPAUSAL SYNDROME; OSTEOPOROSIS; POSTMENOPAUSE;

CONFLICT OF INTEREST; DISCLOSURE; DRUG IMPLANTS; DRUG INDUSTRY; EDITORIAL POLICIES; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MARKETING;

EID: 77956415305     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-010-1360-7     Document Type: Article

References (34)

1. Wilson D. Wyeth's Use of Medical Ghostwriters Questioned. New York Times. December 13, 2008:B1 (Accessed on March 2010 at http://www.nytimes.com/2008/12/ 13/business/13wyeth.html?-r=1&ref=business )
2. JE Rossouw GL Anderson RL Prentice, et al. 2002 Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA 288 321 333 10.1001/jama.288.3.321
3. Million Women Study Collaborators 2003 Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 419 427 10.1016/S0140-6736(03)14065-2
4. AL Hersh ML Stefanick RS Stafford 2004 National use of postmenopausal hormone therapy: annual trends and response to recent evidence JAMA 291 47 53 10.1001/jama.291.1.47
5. J Watson L Wise J Green 2007 Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005 Eur J Clin Pharmacol 63 843 849 10.1007/s00228-007-0320-6
6. ACOG Task Force for Hormone Therapy American College of Obstetricians and Gynecologists Women's Health Care Physicians 2004 Summary of balancing risks and benefits Obstet Gynecol 104 128S 129S 10.1097/01.AOG.0000138791.21105.ce
7. L Mosca LJ Appel EJ Benjamin, et al. 2004 Evidence-based guidelines for cardiovascular disease prevention in women Circulation 109 672 693 10.1161/01.CIR.0000114834.85476.81
8. Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause. 2004;11:589-600.
9. CN Wathen DS Feig JW Feightner BL Abramson AM Cheung 2004 Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care CMAJ 170 1535 1537
10. A Tatsioni NG Bonitsis JP Ioannidis 2007 Persistence of contradicted claims in the literature JAMA 298 2517 2526 10.1001/jama.298.21.2517
11. GC Siontis A Tatsioni DG Katritsis JP Ioannidis 2009 Persistent reservations against contradicted percutaneous coronary intervention indications: citation content analysis Am Heart J 157 695 701 10.1016/j.ahj.2008.11.023
12. Angell M. Drug companies. New York: Oxford University Press; 2004:251.
13. DJ Rothman WJ McDonald CD Berkowitz, et al. 2009 Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest JAMA 301 1367 1372 10.1001/jama.2009.407
14. AD Sniderman CD Furberg 2009 Why guidelinemaking requires reform JAMA 301 429 431 10.1001/jama.2009.15
15. R Steinbrook 2008 Financial support of continuing medical education JAMA 299 1060 1062 10.1001/jama.299.9.1060
16. DJ Rothman 2008 Academic medical centers and financial conflicts of interest JAMA 299 695 697 10.1001/jama.299.6.695
17. SH Ehringhaus JS Weissman JL Sears SD Goold S Feibelmann EG Campbell 2008 Responses of medical schools to institutional conflicts of interest JAMA 299 665 671 10.1001/jama.299.6.665
18. SH Podolsky JA Greene 2008 A historical perspective of pharmaceutical promotion and physician education JAMA 300 831 833 10.1001/jama.300.7.831
19. EG Campbell RL Gruen J Mountford LG Miller PD Cleary D Blumenthal 2007 A national survey of physician-industry relationships N Engl J Med 356 1742 1750 10.1056/NEJMsa064508
20. AS Relman 2007 Medical professionalism in a commercialized health care market JAMA 298 2668 2670 10.1001/jama.298.22.2668
21. TA Brennan DJ Rothman L Blank, et al. 2006 Health industry practices that create conflicts of interest: a policy proposal for academic medical centers JAMA 295 429 433 10.1001/jama.295.4.429
22. J Peppercorn E Blood E Winer A Partridge 2007 Association between pharmaceutical involvement and outcomes in breast cancer clinical trials Cancer 109 1239 1246 10.1002/cncr.22528
23. SC Vlad MP LaValley TE McAlindon DT Felson 2007 Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum 56 2267 2277 10.1002/art.22728
24. JP Ioannidis 2005 Why most published research findings are false PLoS Med 2 e124 10.1371/journal.pmed.0020124
25. JP Ioannidis 2008 Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philos Ethics Humanit Med 3 14 10.1186/1747-5341-3-14
26. HT Stelfox G Chua K O'Rourke AS Detsky 1998 Conflict of interest in the debate over calcium-channel antagonists N Engl J Med 338 101 106 10.1056/NEJM199801083380206
27. NK Choudhry HT Stelfox AS Detsky 2002 Relationships between authors of clinical practice guidelines and the pharmaceutical industry JAMA 287 612 617 10.1001/jama.287.5.612
28. M Angell JP Kassirer 1996 Editorials and conflicts of interest N Engl J Med 335 1055 1056 10.1056/NEJM199610033351410
29. JP Kassirer M Angell 1993 Financial conflicts of interest in biomedical research N Engl J Med 329 570 571 10.1056/NEJM199308193290810
30. MA Steinman LA Bero MM Chren CS Landefeld 2006 Narrative review: the promotion of gabapentin: an analysis of internal industry documents Ann Intern Med 145 284 293
31. D Healy D Cattell 2003 Interface between authorship, industry and science in the domain of therapeutics Br J Psychiatry 183 22 27 10.1192/bjp.183.1.22
32. JS Ross KP Hill DS Egilman HM Krumholz 2008 Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation JAMA 299 1800 1812 10.1001/jama.299.15.1800
33. PC Gøtzsche A Hróbjartsson HK Johansen MT Haahr DG Altman AW Chan 2007 Ghost authorship in industry-initiated randomised trials PLoS Med 4 e19 10.1371/journal.pmed.0040019
34. Conflict of Interest in Medical Research, Education and Practice. Bernard Lo and Marilyn J. Eds. Report prepared by the Committee on Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: Institute of Medicine. National Academy Press; April 28, 2009.